PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Törring, Ove
TI  - FREEDOM Trial Analysis: Denosumab Discontinuation and Associated Fracture Incidence
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 28--28
VI  - 12
IP  - 9
4099  - http://mdc.sagepub.com/content/12/9/28.short
4100  - http://mdc.sagepub.com/content/12/9/28.full
AB  - Patients with osteoporosis who discontinue denosumab have transient increases in bone remodeling and decreases in bone mineral density [Miller PD et al. Bone 2008; Bone HG et al. J Clin Endocrinol Metab 2011], but the effect of discontinuation on fracture risk is not clear. The Phase 3 Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months [FREEDOM; NCT00089791] trial determined the incidence of fractures in postmenopausal patients with osteoporosis after stopping denosumab therapy.